Lifeward Ltd. (LFWD) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 11.16M USD | Liabilities, Current |
| Cash and equivalents | 9.45M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 7.86M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 6.15M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $11.16M | $9.45M | (m) | $7.86M | $6.15M | (m) |
| 2026-03-31 | (m) | $10.63M | $11.42M | (m) | $5.66M | $6.25M | (m) |
| 2025-12-31 | (m) | $12.04M | $2.17M | (m) | $6.14M | $5.73M | (m) |
| 2025-09-30 | (m) | $9.05M | $1.96M | (m) | $6.13M | $7.11M | (m) |
| 2025-06-30 | (m) | $10.36M | $5.14M | (m) | $5.86M | $7.62M | (m) |
| 2025-03-31 | (m) | $9.07M | $5.73M | (m) | $5.17M | $6.80M | (m) |
| 2024-12-31 | (m) | $10.22M | $6.75M | (m) | $6.00M | $6.72M | (m) |
| 2024-09-30 | (m) | $9.66M | $10.65M | (m) | $5.84M | $7.30M | (m) |
| 2024-06-30 | (m) | $9.97M | $15.13M | (m) | $5.27M | $7.19M | (m) |
| 2024-03-31 | (m) | $10.09M | $20.74M | (m) | $3.49M | $6.06M | (m) |
| 2023-12-31 | (m) | $11.79M | $28.08M | (m) | $3.12M | $5.65M | (m) |
| 2023-09-30 | (m) | $12.81M | $32.59M | (m) | $3.53M | $6.04M | (m) |
| 2023-06-30 | (m) | $5.44M | $58.18M | (m) | $774.00K | $3.04M | (m) |
| 2023-03-31 | (m) | $3.88M | $61.88M | (m) | $532.00K | $3.03M | (m) |
| 2022-12-31 | (m) | $4.78M | $67.90M | (m) | $1.04M | $2.93M | (m) |
| 2022-09-30 | (m) | $4.22M | $74.03M | (m) | $447.00K | $3.33M | (m) |
| 2022-06-30 | (m) | $3.80M | $78.83M | (m) | $866.00K | $3.10M | (m) |
| 2022-03-31 | (m) | $3.62M | $82.63M | (m) | $564.00K | $3.23M | (m) |
| 2021-12-31 | (m) | $4.04M | $88.34M | (m) | $585.00K | $2.99M | (m) |
| 2021-09-30 | (m) | $4.38M | $91.23M | (m) | $1.27M | $3.07M | (m) |
| 2021-06-30 | (m) | $4.20M | $64.24M | (m) | $779.00K | $3.35M | (m) |
| 2021-03-31 | (m) | $4.02M | $67.41M | (m) | $498.00K | $3.49M | (m) |
| 2020-12-31 | (m) | $4.67M | $20.35M | (m) | $684.00K | $3.54M | (m) |
| 2020-09-30 | (m) | $7.64M | $18.05M | (m) | $715.00K | $3.71M | (m) |
| 2020-06-30 | (m) | $8.85M | $14.06M | (m) | $1.05M | $3.46M | (m) |
| 2020-03-31 | (m) | $10.35M | $16.60M | (m) | $726.00K | $3.34M | (m) |
| 2019-12-31 | (m) | $10.17M | $16.25M | (m) | $794.00K | $3.12M | (m) |
| 2019-09-30 | (m) | $9.46M | $20.41M | (m) | $572.00K | $2.98M | (m) |
| 2019-06-30 | (m) | $8.37M | $24.05M | (m) | $417.00K | $2.66M | (m) |
| 2019-03-31 | (m) | $7.27M | $8.86M | (m) | $1.09M | $2.48M | (m) |
| 2018-12-31 | (m) | $5.38M | $9.55M | (m) | $758.00K | $2.24M | (m) |
| 2018-09-30 | (m) | $11.05M | $5.23M | (m) | $1.16M | $2.47M | (m) |
| 2018-06-30 | (m) | $11.07M | $9.09M | (m) | $1.86M | $3.02M | (m) |
| 2018-03-31 | (m) | $10.80M | $8.82M | (m) | $1.57M | $3.48M | (m) |
| 2017-12-31 | (m) | $9.73M | $14.57M | (m) | $1.10M | $3.64M | (m) |
| 2017-09-30 | (m) | $9.62M | $12.93M | (m) | $1.26M | $3.50M | (m) |
| 2017-06-30 | (m) | $11.81M | $16.25M | (m) | $1.11M | $3.42M | (m) |
| 2017-03-31 | (m) | $12.84M | $17.13M | (m) | $1.40M | $3.05M | (m) |
| 2016-12-31 | (m) | $12.40M | $23.68M | (m) | $1.25M | $3.26M | (m) |
| 2016-09-30 | (m) | $10.50M | $12.40M | (m) | $944.00K | $3.42M | (m) |
| 2016-06-30 | (m) | $9.84M | $15.69M | (m) | $1.19M | $3.42M | (m) |
| 2016-03-31 | (m) | $7.30M | $21.81M | (m) | $2.44M | $3.06M | (m) |
| 2015-12-31 | (m) | $4.34M | $17.87M | (m) | $2.15M | $2.53M | (m) |
| 2015-09-30 | (m) | (m) | $25.14M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $31.17M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | $36.96M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $3.57M | $41.83M | (m) | $1.96M | $777.00K | (m) |
| 2013-12-31 | (m) | $1.90M | $8.86M | (m) | $304.00K | $973.00K | (m) |
| 2012-12-31 | (m) | (m) | $769.00K | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $559.00K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENvue Medical, Inc. (FEED) | United States | $0.011B | |
| MILESTONE SCIENTIFIC INC. (MLSS) | United States | $0.036B | -6.85 |
| Bone Biologics Corp (BBLG) | United States | $0.001B | |
| LogicMark, Inc. (LGMK) | United States | $0.000B | |
| ALPHA PRO TECH LTD (APT) | $0.052B | 13.63 | |
| Envoy Medical, Inc. (COCH) | United States | $0.056B | |
| MYOMO, INC. (MYO) | United States | $0.065B | -2.85 |
| Safe Pro Group Inc. (SPAI) | United States | $0.090B | |
| LAKELAND INDUSTRIES INC (LAKE) | United States | $0.104B | -4.21 |
| NutriBand Inc. (NTRB) | United States | $0.109B |